PLACENTEX * CREAM 25G 0.08%
Therapeutic indications
For parenteral use. PLACENTEX "5.625 mg / 3ml solution for injection", PLACENTEX "2.25 mg / 3ml solution for injection" Connective disorders based on dystrophic or dystrophic-ulcerative: healing, antidystrophic. For external use. PLACENTEX "0.08% cream" Skin and connective tissue disorders on a dystrophic or dystrophic-ulcerative basis: healing, antidystrophic. PLACENTEX "0.75 mg / 3ml cutaneous solution" Connective disorders based on dystrophic or ulcerative dystrophic: healing, antidystrophic. PLACENTEX "0.75 mg / ml eye drops" Dystrophic-ulcerative diseases of the conjunctiva and cornea: microtrauma from contact lenses, healing.
Dosage and method of use
PLACENTEX "5.625 mg / 3ml solution for injection", PLACENTEX "2.25 mg / 3ml solution for injection" 1 ampoule per day intramuscularly or subcutaneously, for cycles of 15-20 days repeatable or according to medical prescription. PLACENTEX "0.08% cream" local applications once or twice a day or according to medical prescription. PLACENTEX "0.75 mg / 3 ml cutaneous solution" local applications 1 or 2 times a day, soaking sterile gauze or according to medical prescription. PLACENTEX "0.75 mg / ml eye drops" 2 or 3 drops in the conjunctival fornix 2-4 times a day or according to medical prescription.
Contraindications
Hypersensitivity to the active substance or to one of the excipients.
Side effects
Reporting of suspected adverse reactions Reporting of suspected adverse reactions occurring after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of the Italian Medicines Agency Website: http://www.agenziafarmaco.gov.it/it/responsabili
Special warnings
The product is neither addictive nor risk of drug addiction. In case of subjective hypersensitivity to the component, suspend the administration and, if necessary, initiate medical desensitizing therapy. No particular precautions for use emerged.
Pregnancy and breastfeeding
There is no or limited amount of data on the use of Placularx in pregnant women.
Expiration and retention
No special storage precautions. Store Placularx away from heat sources and protected from light.
Interactions with other drugs
No interaction studies have been performed.
Overdose
No cases of overdose have been reported.
Active principles
Pharmaceutical Forms for parenteral use: PLACENTEX "5.625 mg / 3 ml solution for injection" 1 ampoule of 3 ml contains: Active Ingredient: Polydexoxyribonucleotide 5.625 mg PLACENTEX "2.25 mg / 3 ml solution for injection" 1 ampoule of 3 ml contains: Active ingredient: Polydexoxyribonucleotide 2.25 mg. Pharmaceutical Forms for external use: PLACENTEX "0.08% cream" 25 g tube contains: Active Ingredient: Polydexoxyribonucleotide 80 mg PLACENTEX "0.75 mg / 3 ml cutaneous solution" 1 ampoule of 3 ml contains: Active Ingredient: Polydexoxyribonucleotide 0.75 mg PLACENTEX "0.75 mg / ml eye drops" a 10 ml dropper bottle contains: Active Ingredient: 7.5 mg polydesoxyribonucleotide
Excipients
PLACENTEX "5.625 mg / 3ml solution for injection": sodium chloride; water ppi PLACENTEX "2.25 mg / 3ml solution for injection": sodium chloride; water ppi PLACENTEX "0.08% cream": esters of oleic acid of decyl alcohol, cetylstearyl alcohol, anhydrous lanolin, alkyl p-hydroxy benzoates, imidazolidinylurea, aromatic base, purified water. PLACENTEX "0.75 mg / 3ml cutaneous solution" sodium chloride; ppi water PLACENTEX "0.75 mg / ml eye drops" polyvinylpyrrolidone, methyl-p-hydroxy benzoate, propyl-p-hydroxy benzoate, sodium edetate, monobasic sodium phosphate, dibasic sodium phosphate, ppi water
Convenient and safe payments
Shipping in 48h-72h all over the world
Fast returns
Pharmaceutical experience
